An opioid 10 times stronger than fentanyl, a reformulated asthma inhaler & more: 5 latest FDA approvals

Here are five drugs or medical devices that have been approved by the FDA since Nov. 2:

Advertisement

1. Dsuvia is a tablet version of an opioid that dissolves under the tongue for quick pain relief. It is 10 times stronger than fentanyl.

2. Primatene Mist, which has been reformulated, is an over-the-counter aerosol inhaler for the temporary relief of mild asthma symptoms.

3. Udenyca, approved to decrease the incidence of infection by helping the body make white blood cells after receiving cancer medications, is a biosimilar of Neulasta.

4. The Fluobeam 800 Clinic Imaging Device was approved to help surgeons detect parathyroid tissue during surgical procedures to remove the thyroid or parathyroid gland. The device uses a light that causes the parathyroid tissue to emit a fluorescent glow.

5. The Parathyroid Detection PTeye System helps surgeons detect parathyroid tissue during surgery by using a probe that emits fluorescence light. 

More articles on supply chain:
Amazon to sell exclusive brand of consumer medical devices
The 1st flu treatment in decades, a diagnostic test for menopause & more: 5 latest FDA approvals
Senate Democrats question if FDA’s digital health pre-certification will ‘compromise public safety’

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

How University Health turns ED signals into hospital-wide flow

Thursday, August 13
1:00 PM - 2:00 PM CDT

Presenters: Bill Phillips, University HealthAshley Schutz, MHA, MLS (ASCP), University HealthBill Griffith

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.